JCR Pharma 
Welcome,         Profile    Billing    Logout  
 11 Products   84 Diseases  11 Products   15 Trials   447 News 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ryoncil (remestemcel-L) / Mallinckrodt, Mesoblast
Mesoblast_COVID-19: Remestemcel-L Looks Promising in COVID-19 Patients With Moderate to Severe ARDS

Not yet recruiting
3
0
US
Ryoncil (remestemcel-L) - Mallinckrodt, Mesoblast, JCR Pharma
Mesoblast, JCR Pharma, Mallinckrodt
Moderate to Severe ARDS
 
 
NCT04548583: Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

Recruiting
1/2
24
US
Remestemcel-L, Placebo
The Cleveland Clinic, Mesoblast, Inc.
Crohn Colitis
10/23
10/23
NCT04543994: Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

Recruiting
1/2
24
US
Remestemcel-L, Placebo
The Cleveland Clinic, Mesoblast, Inc.
Ulcerative Colitis
11/23
11/23
NCT00759018: Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD

Checkmark In pediatric patients with GVHD at BMT Tandem 2016
Feb 2016 - Feb 2016: In pediatric patients with GVHD at BMT Tandem 2016
No Longer Available
N/A
Canada, US
remestemcel-L, Prochymal®, Ex-vivo Cultured Adult Human Mesenchymal Stem Cells
Mesoblast, Inc.
Graft vs Host Disease, Graft-Versus-Host Disease
 
 
NCT00826046: Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

No Longer Available
N/A
US
Prochymal®, Ex-vivo Cultured Adult Human Mesenchymal Stem Cells
Mesoblast, Inc.
Graft-Versus-Host Disease
 
 
NCT01510431: Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease

No Longer Available
N/A
US
PROCHYMAL (remestemcel-L)
Mesoblast, Inc.
Crohn's Disease
 
 
NCT04366830: Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

No Longer Available
N/A
US
Remestemcel-L
Mesoblast International Sàrl
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
 
 
NCT04456439: Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Available
N/A
NA
Remestemcel-L, Hydrocortisone, Diphenhydramine, Benadryl®
Mesoblast International Sàrl
Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
 
 
recombinant-iduronate-2-sulfatase (JR-032) / GSK, JCR Pharma
STARLIGHT, NCT04573023 / 2020-003200-14: A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II

Recruiting
3
80
Europe, US, RoW
JR-141, Idursulfase, JR-141 or Idursulfase
JCR Pharmaceuticals Co., Ltd., JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis II
01/26
01/26
Izcargo (pabinafusp alfa) / JCR Pharma
NCT05594992: An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects

Enrolling by invitation
3
80
Europe, US, RoW
JR-141
JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis II
02/28
02/28
NCT04348136: An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Active, not recruiting
2/3
27
Japan
JR-141
JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis II
03/30
03/30
NCT03708965: An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

Active, not recruiting
2
19
RoW
JR-141
JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis II
03/24
03/24
lepunafusp alfa (JR-171) / JCR Pharma
NCT04453085: An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)

Active, not recruiting
1/2
14
Japan, US, RoW
JR-171, lepunafusp alfa
JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis I
05/25
05/25
JR-441 / JCR Pharma
2022-002314-17: Phase I/II study of weekly infusions of JR-441 in patients with mucopolysaccharidosis type IIIA

Not yet recruiting
1/2
12
Europe
JR-441, Powder for solution for injection
JCR Pharmaceuticals Co., Ltd., JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis type IIIA (MPS IIIA)MPS III is an autosomal recessive disease characterized by the accumulation of HS in the tissues throughout the body due to a deficiency in enzymes involved in glycosaminoglycan (GAG) degradation in lysosomes. In MPSIII type A the deficient enzyme is SGSH. MPS IIIA has an estimated birth prevalence of between 0.26 and 1.89 per 100,000 live births and manifests as a severe neurodegenerative disease with progressive developmental regression., MPS IIIA is a condition that affects the brain. It can negatively impact how a person thinks and behaves. It can lead to difficulties with walking and sleeping, chest and ear infections, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NCT06095388 / 2022-002314-17: Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Recruiting
1/2
12
Europe
JR-441, posnafusp alfa
JCR Pharmaceuticals Co., Ltd., JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis III-A
10/29
10/29
JR-446 / JCR Pharma
NCT06488924: An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

Recruiting
1/2
10
Japan
JR-446
JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis III-B
06/26
12/28
JR-479 / JCR Pharma
No trials found
recombinant N-sulphoglucosamine sulphohydrolase (AGT184) / JCR Pharma
No trials found
AGT187 / JCR Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ryoncil (remestemcel-L) / Mallinckrodt, Mesoblast
Mesoblast_COVID-19: Remestemcel-L Looks Promising in COVID-19 Patients With Moderate to Severe ARDS

Not yet recruiting
3
0
US
Ryoncil (remestemcel-L) - Mallinckrodt, Mesoblast, JCR Pharma
Mesoblast, JCR Pharma, Mallinckrodt
Moderate to Severe ARDS
 
 
NCT04548583: Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

Recruiting
1/2
24
US
Remestemcel-L, Placebo
The Cleveland Clinic, Mesoblast, Inc.
Crohn Colitis
10/23
10/23
NCT04543994: Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

Recruiting
1/2
24
US
Remestemcel-L, Placebo
The Cleveland Clinic, Mesoblast, Inc.
Ulcerative Colitis
11/23
11/23
NCT00759018: Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD

Checkmark In pediatric patients with GVHD at BMT Tandem 2016
Feb 2016 - Feb 2016: In pediatric patients with GVHD at BMT Tandem 2016
No Longer Available
N/A
Canada, US
remestemcel-L, Prochymal®, Ex-vivo Cultured Adult Human Mesenchymal Stem Cells
Mesoblast, Inc.
Graft vs Host Disease, Graft-Versus-Host Disease
 
 
NCT00826046: Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

No Longer Available
N/A
US
Prochymal®, Ex-vivo Cultured Adult Human Mesenchymal Stem Cells
Mesoblast, Inc.
Graft-Versus-Host Disease
 
 
NCT01510431: Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease

No Longer Available
N/A
US
PROCHYMAL (remestemcel-L)
Mesoblast, Inc.
Crohn's Disease
 
 
NCT04366830: Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

No Longer Available
N/A
US
Remestemcel-L
Mesoblast International Sàrl
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
 
 
NCT04456439: Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Available
N/A
NA
Remestemcel-L, Hydrocortisone, Diphenhydramine, Benadryl®
Mesoblast International Sàrl
Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
 
 
recombinant-iduronate-2-sulfatase (JR-032) / GSK, JCR Pharma
STARLIGHT, NCT04573023 / 2020-003200-14: A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II

Recruiting
3
80
Europe, US, RoW
JR-141, Idursulfase, JR-141 or Idursulfase
JCR Pharmaceuticals Co., Ltd., JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis II
01/26
01/26
Izcargo (pabinafusp alfa) / JCR Pharma
NCT05594992: An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects

Enrolling by invitation
3
80
Europe, US, RoW
JR-141
JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis II
02/28
02/28
NCT04348136: An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Active, not recruiting
2/3
27
Japan
JR-141
JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis II
03/30
03/30
NCT03708965: An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

Active, not recruiting
2
19
RoW
JR-141
JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis II
03/24
03/24
lepunafusp alfa (JR-171) / JCR Pharma
NCT04453085: An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)

Active, not recruiting
1/2
14
Japan, US, RoW
JR-171, lepunafusp alfa
JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis I
05/25
05/25
JR-441 / JCR Pharma
2022-002314-17: Phase I/II study of weekly infusions of JR-441 in patients with mucopolysaccharidosis type IIIA

Not yet recruiting
1/2
12
Europe
JR-441, Powder for solution for injection
JCR Pharmaceuticals Co., Ltd., JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis type IIIA (MPS IIIA)MPS III is an autosomal recessive disease characterized by the accumulation of HS in the tissues throughout the body due to a deficiency in enzymes involved in glycosaminoglycan (GAG) degradation in lysosomes. In MPSIII type A the deficient enzyme is SGSH. MPS IIIA has an estimated birth prevalence of between 0.26 and 1.89 per 100,000 live births and manifests as a severe neurodegenerative disease with progressive developmental regression., MPS IIIA is a condition that affects the brain. It can negatively impact how a person thinks and behaves. It can lead to difficulties with walking and sleeping, chest and ear infections, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NCT06095388 / 2022-002314-17: Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Recruiting
1/2
12
Europe
JR-441, posnafusp alfa
JCR Pharmaceuticals Co., Ltd., JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis III-A
10/29
10/29
JR-446 / JCR Pharma
NCT06488924: An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

Recruiting
1/2
10
Japan
JR-446
JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis III-B
06/26
12/28
JR-479 / JCR Pharma
No trials found
recombinant N-sulphoglucosamine sulphohydrolase (AGT184) / JCR Pharma
No trials found
AGT187 / JCR Pharma
No trials found

Download Options